Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
60.7M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
39.4M
-
Shares change
-
-2.15M
-
Total reported value, excl. options
-
$43.3M
-
Value change
-
-$3.63M
-
Put/Call ratio
-
1.37
-
Number of buys
-
25
-
Number of sells
-
-40
-
Price
-
$1.10
Significant Holders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) as of Q1 2025
91 filings reported holding ABOS - Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share as of Q1 2025.
Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.4M shares
of 60.7M outstanding shares and own 64.96% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (14.9M shares), Sands Capital Ventures, LLC (3.42M shares), FRANKLIN RESOURCES INC (3.14M shares), BlackRock, Inc. (2.33M shares), FMR LLC (2.03M shares), VANGUARD GROUP INC (1.94M shares), Knollwood Investment Advisory, LLC (1.63M shares), MILLENNIUM MANAGEMENT LLC (1.14M shares), Pathstone Holdings, LLC (1.09M shares), and Alyeska Investment Group, L.P. (940K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.